



Health, Seniors and Long-Term Care
Public Health
300 Carlton Street
Winnipeg, Manitoba Canada R3B 3M9

July 3, 2025

RE: Pneumococcal Conjugate 20-valent Vaccine Eligibility Update for High-Risk Individuals

Dear Health Care Provider,

Manitoba Health, Seniors and Long-Term Care is updating the pneumococcal conjugate 20-valent (Pneu-C-20) vaccine eligibility for high-risk individuals 65 years and older to align with the high-risk eligibility criteria for individuals 2 months to 64 years of age, effective immediately. The criteria include the following:

- Chronic cerebral spinal fluid (CSF) leak
- Chronic neurologic condition that may impair clearance of oral secretions
- Cochlear implants (including those children who are to receive implants)
- Chronic cardiac or pulmonary disease
- Diabetes mellitus
- Asplenia (functional or anatomic)
- Hemoglobinopathies
- Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
- Acquired complement deficiency
- Hematopoietic stem cell transplant recipients (as per [CancerCare Manitoba Blood and Marrow Transplant \(BMT\) Immunization Schedule](#))
- CAR T-cell therapy recipients (as per [CancerCare Manitoba CAR-T Immunization Schedule](#))
- HIV infection
- Immunosuppressive therapy including use of long-term corticosteroids, post-organ transplant therapy, and certain anti-rheumatic drugs
- Chronic kidney disease, including nephrotic syndrome and chronic renal failure
- Chronic liver disease (including hepatic cirrhosis due to any cause)
- Solid organ or islet transplant (candidate or recipient)
- Residents of a personal care home or a long-term care facility OR in residential care due to complex medical needs
- Persons with alcoholism
- Persons who are homeless
- Persons who use illicit drugs

All individuals 65 years and older who meet the high-risk criteria listed above are eligible to receive one dose of Pneu-C-20 vaccine, provided it has been at least 5 years after any previous dose of Pneu-P-23 or at least 8 weeks after any previous dose of Pneu-C-13 vaccine, whichever is longer.

Please, refer to www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html for eligibility criteria for publicly-funded vaccines in Manitoba.

If you have any questions, please email vaccines@gov.mb.ca.

Please, share as you deem appropriate.

Thank you.

Sincerely,

"Original Signed by"

Richard Baydack, PhD
Director
Communicable Disease Control

"Original Signed by"

Natalie Casclang, MD, CCFP, FRCPC
Medical Officer of Health,
Communicable Disease Control